MspA-83M plasmid from Shuo Huang

   Sequence by GenScript        Sequence by Depositor

MspA-83M

Cat. No.:
MC_0101203
Availability:
4 µg of lyophilized plasmid
(1 µg for low-copy plasmid)
Price:
$65
  • General
  • Specification
  • Comments (0)
  • Keywords Expression
    Vector Backbone pET-30a (+)
    Source Member Deposit
    Depositor Shuo Huang
    Organization Nanjing University
    Description The plasmid MspA-83M (T83M/D90N/D91N/D93N/D118R/D134R/E139K) is designed for the preparation of a mutant Mycobacterium smegmatis porin A (MspA) nanopore, which is engineered with a methionine at the site 83. It only has a single amino acid difference at the site 83 from the previously reported M2 MspA (D90N/D91N/D93N/D118R/D134R/E139K) (Proc. Natl. Acad. Sci., 2008, 105, 20647-20652), which has been applied in DNA sequencing (Nat. Biotechnol., 2012, 30, 349-353). MspA (PDB ID: 1UUN) possesses a narrow and short pore constriction, measuring ~1.2 nm at its narrowest spot and ~1.0 nm in an overall length. With this advantageous geometry, MspA exhibits an excellent sensing performance as a nanoreactor to probe single-molecule reactions (Nat. Commun., 2019, 10, 5668.; Chem. Sci., 2020,11, 879-887.; Anal. Chem. 2021, 93, 3, 1529–1536). The reported engineering of MspA to form corresponding nanoreactor has focused only on site 91. In our work, other potential engineering sites of MspA have been thoroughly investigated. The amino acid at the site 83 is located around the pore constriction and has a lumen-facing orientation. The MspA-83M mutant is designed to map the potential reactive sites within MspA to form a nanoreactor. The structure of the mutant, and its sensing performance to a model reactant (tetrachloroaurate(III) ion) are investigated. It is revealed that the sensing performance is inversely correlated to the cross-sectional diameter of the pore constriction size of the engineering site (ACS Sens. 2021. DOI: 10.1021/acssensors.1c00792.).
    Publication Zhang, J., Cao, J., Jia, W. et al. Mapping potential engineering sites of Mycobacterium smegmatis porin A (MspA) to form a nanoreactor. ACS Sensors 2021. DOI: 10.1021/acssensors.1c00792.
    Plasmid Copy High Copy
    Bacterial Resistance Kanamycin
    Growth Strain DH5-Alpha
    Growth Temperature 37°C
    Plasmid Size (bp) 5829
    *This material may be covered by one or more patents, trademarks and/or copy rights owned or controlled by Depositors or any third parties. This material is available to academic and nonprofit organizations for research use only. Please contact MolecularCloud at plasmid@genscript.com and the Depositor directly if you are from industrial institute or attempt for profit application. This material is not intended to be used therapeutic or diagnostic purposed in humans or animals.
    Customers who viewed this item also viewed:

    pCas

    Constitutive expression of Cas9 together with inducible expression of lambda RED and sgR

    pCAGO

    CRISPR/Cas9-assisted gRNA-free one-step genome editing

    pUC57-2019-nCoV-PC:RdRP

    This plasmid contains part of 2019-nCoV(SARS-CoV-2) RdRP gene and can be used as positive control for the detection of 2019-nCoV(SARS-CoV-2) by qRT-PCR

    pUC57-2019-nCoV-S(Original)

    This plasmid contains the encoding gene of 2019-nCoV(SARS-CoV-2) surface glycoprotein (original sequence)

    pUC57-2019-nCoV-S(Human)

    This plasmid contains the encoding gene of 2019-nCoV(SARS-CoV-2) surface glycoprotein (Codon optimized for Human expression system)

    pUC57-2019-nCoV-N

    This plasmid contains the encoding gene of 2019-nCoV(SARS-CoV-2) nucleocapsid phosphoprotein (original sequence)

    pcDNA3.1+/C-(K)DYK-ACE2 (NM_021804.2, OHu20260)

    Homo sapiens angiotensin I converting enzyme 2 (ACE2), the receptor for 2019-nCoV(SARS-CoV-2).

    2019-nCov_pcDNA3.1(+)-P2A-eGFP

    The plasmid is used for 2019-nCoV(SARS-CoV-2) surface glycoprotein expression (Codon Optimized for Mouse expression system). The surface glycoprotein is integrated with eGFP protein through P2A, which can be used for flow cytometry antibody screening or immunological research.
    #[first_name]
    #[create_date]
    #[comment]
    Reply(#[reply_num])
    #[like_num]
  • #[first_name]
    #[create_date]
    #[comment]
    Reply
    #[like_num]